Oct 5 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO :
* Announces settlement in patent litigation for Absorica
* Says entered into a settlement agreement with Actavis (NYSE:AGN) Laboratories
* Says Cipher, Ranbaxy and Galephar entered into a non-exclusive license
agreement with Actavis as part of the settlement
* Says Actavis may begin selling its generic version of Absorica in U.S. on
December 27, 2020 or earlier under certain circumstances
* Says settlement agreement is subject to review by the U.S. Federal Trade
Commission and U.S. Department of Justice
* Source text for Eikon ID:nCNWrsJNCa
* Further company coverage CPH.TO